Jie-Ling Jiang

Jie-Ling Jiang

Auto-generated profile, based on publicly available information

Jie-Ling Jiang

Shanghai Institute of Hematology, Blood & Marrow Transplantation Center, Collaborative Innovation Center of Hematology, Department of Hematology, Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2025 in Science
Verified
Journal Article
Closed access
JWJingying Wu
Jingying Wu
YWYafei Wang
Yafei Wang
XLXiaoyu Li
Xiaoyu Li
POPei Ouyang
Pei Ouyang
YCYuanyuan Cai
Yuanyuan Cai
BPBo Peng
Bo Peng
Colony-stimulating factor 1 receptor ( CSF1R ) is primarily expressed in microglia. Its monoallelic mutation causes CSF1R-associated microgliopathy (CAMP), a major form of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) and a fatal neurological disease without clinical cure. We developed mouse models harboring human hotspot mutations of CAMP and replaced CSF1R-deficient microglia with CSF1R-normal cells through microglia replacement by bone marrow transplantation (Mr BMT), which attenuated pathology in mice. We further demonstrated that, in the context of CSF1R deficiency, traditional bone marrow transplantation (tBMT) in ALSP functions similarly to Mr BMT, efficiently replacing microglia and reducing disease progression. We then replaced CSF1R-deficient microglia in eight patients by tBMT. The disease progression was halted during the 24-month follow-up. Together, microglia replacement corrects pathogenic mutations and halts disease progression in mice and humans.

30 May 2023 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
JJJie-Ling Jiang
Jie-Ling Jiang
WGWen-Hui Gao
Wen-Hui Gao
LWLi-Ning Wang
Li-Ning Wang
MWMing Wan
Ming Wan
LWLing Wang
Ling Wang
JHJiong Hu
Jiong Hu
Relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) with standard myeloablative conditioning regimens such as Flu-Bu (fludarabine and busulfan) remains a major concern in patients with myeloid malignancies. A low relapse rate was reported when thiotepa or melphalan (Mel) were added to Flu-Bu, but this might increase the non-relapse mortality (NRM). Here, we evaluated the outcomes of 100 patients (70 acute myeloid leukemia, 23 myelodysplastic syndrome, 4 chronic myelomonocytic leukemia, and 3 granulocytic sarcoma) who received their first allo-HSCT after moderate-dose FBM conditioning regimen (fludarabine 150 mg/m2, busulfan 6.4 mg/kg, and melphalan 140 mg/m2, n=69; or lower-dose melphalan at 100 mg/m2 for patients over 55 years old and/or those with HCT-CI ≥3, n=31). The donors were HLA-matched siblings (n=19), unrelated donors (n=4), and haplo-identical donors (n=77). A total of 88% patients had an intermediate or high disease risk index (DRI). Out of 96 evaluable patients, 94 achieved neutrophil engraftment and had full donor chimerism on day 30. After a median follow-up of 468 days (range, 55-1039 days), only four patients relapsed with 2-year cumulative incidence of relapse (CIR) of 5.3%±3.6%. The 100-day and 2-year NRM were 6.8%±4.4% and 12.3%±3.6%, respectively. At last follow-up, the 2-year disease-free survival (DFS) and overall survival (OS) were 82.4%±4.2% and 80.3%±6.0%, respectively. Moreover, when comparing the transplantation outcomes between patients with melphalan 100 mg/m2 and 140 mg/m2, the NRM and CIR were not significantly different and the 2-year DFS and OS were similar in both groups, although the Mel 100 group was associated with a higher median age (58 vs 42 years, p<0.001) and a higher percentage of patients with HCT-CI ≥3 (p=0.005). For the whole group, the only independent factor associated with transplantation outcomes was HCT-CI ≥3, which led to higher NRM and inferior DFS and OS. Our study suggested that moderate-intensity FBM conditioning was feasible for patients with myeloid malignancies with a low relapse rate without increased NRM. A lower dose of melphalan at 100 mg/m2 maintained the low relapse risk without excess NRM for older adults. However, the FBM regimen should be used with caution in patients with high-risk HCT-CI (≥3).

18 March 2021 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
JJJie-Ling Jiang
Jie-Ling Jiang
WGWen-Hui Gao
Wen-Hui Gao
LWLi-Ning Wang
Li-Ning Wang
MWMing Wan
Ming Wan
LWLing Wang
Ling Wang
JHJiong Hu
Jiong Hu
The PT-Cy was considered as one of the mainstay protocol for graft verus host disease (GVHD) prophylaxis. Recent study demonstrated that PT-Cy combined with other immunosuppressants could further reduce the incidence of GVHD and improve the GVHD and relapse free survival (GRFS). In this prospective phase II study, we evaluated the effect of a new GVHD prophylaxis consist of PT-Cy combined with tacrolimus and low dose anti-thymoglobulin (ATG). A total of 23 patients were enrolled including 20 patients with acute lymphoblastic leukemia (ALL) and three patients with T cell lymphoma. The median age was 29 years (range, 16~58 years). Patients with HLA-matched related donor (MSD, n=7) received PT-Cy combined with tacrolimus, while patients with HLA matched unrelated (MUD, n = 2) or haplo-identical (Haplo, n = 14) donor received additional ATG at 2.5 mg/kg on day 15 or day 22 after engraftment of neutrophils. As to the acute GVHD (aGVHD), only three patients developed grade I (n = 1) or grade II (n = 2) aGVHD with 100-day incidence of all aGVHD and II-IV aGVHD at 13.0 ± 5.1% and 9.1 ± 6.1% respectively. Only two patients had mild and one had moderate chronic GVHD (cGVHD), with 1-year incidence of cGVHD and moderate/severe cGVHD at 15.2 ± 8.7% and 4.6 ± 4.4% respectively. A high incidence of CMV reactivation was documented (14/16 with MUD/Haplo donor and 2/7 with MSD) with only 1 CMV disease documented. There were two EBV reactivation without post-transplantation lymphoproliferative disease (PTLD) documented. With a median follow-up of 303 days (range, 75~700 days), three patients relapsed leading to 1-year cumulative incidence of relapse (CIR) at 12.8 ± 9.2%. Only one patient died of CMV pneumonia on day 91 with both 100-day and 1-year non-relapse mortality (NRM) at 4.6 ± 4.4%. The 1-year overall survival (OS), event-free survival (EFS) and GRFS were 95.5 ± 4.4%, 82.6 ± 9.5%, and 68.0 ± 11.3% respectively. Based on Simon's stage II design, our primary data showed that the PT-Cy+tacrolimus ± ATG protocol was promising in preventing aGVHD and cGVHD, which may translate into low NRM without increased CIR. Further clinical trial with large number of patients should be warranted. This trial was registered at www.clinicaltrials.gov as #NCT 04118075.

8 July 2024 in eJHaem
Verified
Journal Article
Open access
JJJieling Jiang
Jieling Jiang
XLXiaofan Li
Xiaofan Li
DWDong Wu
Dong Wu
QLQuanyi Lu
Quanyi Lu
KMKourong Miao
Kourong Miao
JHJiong Hu
Jiong Hu
Relapse remains the main cause of treatment failure in patients with myeloid malignancies even after allogeneic hematopoietic stem cell transplantation (allo‐HSCT). We observed a particularly low incidence of relapse in patients prepared with fludarabine, busulfan and melphalan in our previous study and this multicenter retrospective analysis aimed to confirm the feasibility of the regimen and to identify the potential prognostic factors. This study was performed using registry data from adults patients with myeloid malignancies who underwent their first allo‐HSCT following fludarabine(≥100 mg/m2), busulfan (≥3.2 mg/kg) and melphalan (≥100 mg/m2) based conditioning at nine transplantation centers in China between Jan. 2020 and Mar. 2022. A total of 221 consecutive patients (AML n = 171, MDS‐IB‐1 or 2 n = 44, CMML n = 6) with median age of 46 were enrolled in this study. The median follow‐up was 507 days for survivors. The 2‐year NRM, CIR, OS and DFS were 10.6% ± 2.2%, 14.8% ± 3.3%, 79.4% ± 3.7% and 74.6% ± 3.7%, respectively. In multivariate analyses, high HCT‐CI (≥3) was the only independent factor for higher NRM [hazard ratio (HR), 2.96; 95% confidence interval (CI), 1.11 to 7.90; p = 0.030] and ECOG score ≥2 was the only independent factor for inferior OS (HR, 2.43; 95%CI, 1.15 to 5.16; p = 0.020) and DFS (HR, 2.12; 95%CI, 1.13 to 4.02; p = 0.020). AML diagnosis and positive measurable residual disease (MRD) at transplantation were predictors for higher CIR (HR = 7.92, 95%CI 1.05‐60.03, p = 0.045; HR = 3.64, 95%CI 1.40‐9.44, p = 0.008; respectively), while post‐transplantation cyclophosphamide based graft‐versus‐host disease prophylaxis was associated with lower CIR (HR = 0.24 95%CI 0.11‐0.54, p = 0.001). The intensity of conditioning regimen did not impact CIR, NRM, DFS and OS. These results supported that double alkylating agents of busulfan and melphalan based conditioning regimens were associated with low relapse rate and acceptable NRM in adult patients with myeloid malignancies. The optimal dose remained to be confirmed by further prospective studies.

24 March 2022 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
JJJie-Ling Jiang
Jie-Ling Jiang
MCMing Chen
Ming Chen
LWLi-Ning Wang
Li-Ning Wang
MWMin Wan
Min Wan
WGWen-Hui Gao
Wen-Hui Gao
JHJiong Hu
Jiong Hu

29 November 2018 in Blood
Verified
Journal Article
Open access
JYJun Yang
Jun Yang
JJJiang Jieling
Jiang Jieling
YCYu Cai
Yu Cai
SLSu Li
Su Li
LWLiping Wan
Liping Wan
XSXianmin Song
Xianmin Song
Background:Nowadays, the most wildly used regimens for graft-versus-host disease (GvHD) prophylaxis in haplo-hematopoietic stem cell transplantation (Haplo-HSCT) were based on in vivo T cell depletion (TCD) with anti-thymocyte globulin (ATG) or post-transplant cyclophosphamide (PTCy). To improve the efficiency of GvHD prophylaxis in haploidentical peripheral blood stem cell transplantation (Haplo-PBSCT), a novel regimen, which is composed of low dose of ATG (5 mg/kg) and low dose PTCy (50mg/kg) for GvHD prophylaxis, was evaluated in a prospective phase II clinical trial (Clinicaltrials.org NCT03395860). Method:Thirty-two patients with hematological malignancies were enrolled in this trial. Median age was 37 years (range, 20 to 62 years). At the time of transplantation, a total of fourteen patients with AML/ALL reached first or subsequent complete response (CR1, ≥CR2); the other eighteen patients had active disease including three ALL, three MDS-EB II, two CMML and ten AML patients. All patients received myeloablative conditioning regimens except for three patients. The GvHD prophylaxis contained ATG 2.5mg/kg administered on day -2 to -1 and cyclophosphamide (Cy) 50 mg/kg on day +3, cyclosporine A (CsA) and mycophenolate mofetil (MMF) initiating on day +4. The PBSC grafts for all patients were mobilized with G-CSF. Unrelated cord blood (UBC) was infused as the third party cells at 4 hours before PBSC graft infusion Results: All patients received PBSC grafts with MNCs 15.5 (7.5-28.3) ×108/kg and CD34+ cells 13.39 (2.4-31.7) ×106/kg. The median nuclear cell number and CD34+ cell number of unrelated third party cord blood were 2.1 (1.4-4.14) ×107/kg and 5.6 (1.52-11.2) ×104/kg, respectively. The median time for neutrophil and platelet engraftment was 12 days (range 9-20) and 16 days (range 12-25), respectively. Chimerism monitoring showed that all the patients were fully donor chimerism between days 14 to 28 after transplantation. There was no chimerism of cord blood cells in all patients on days 14 after transplantation. Primary graft failure occurred in one patient (3.1%).One patient with AML experienced secondary graft failure after CMV pneumonia at day 90. The cumulative incidences (CIs) of grades II-IV and III-IV acute GvHD were 19.4% (95% CI, 5.5-33.3%) (Figure A) and 6.9% (95% CI 0-16.3%) (Figure B) by day 100, respectively. The CIs within six months of moderate-to-severe cGVHD were 18.8% (5/27 cases) (95% CI, 3.9%-33.7%)(Figure C). No patient died from acute and chronic GvHD. The one-year probability of relapse was 25.1% (95% CI, 7.3-42.9%)(Figure D). The one-year probabilities of disease free-survival (DFS) and overall survival (OS) were 59% (95% CI, 33.3%-84.7%) and 78.4% (95% CI, 63%-93.8%)(Figure E), respectively. The CIs of CMV reactivation and EBV reactivation by day 180 were 37.5% (95% CI, 19.8-55.2%) and 40.6% (95% CI, 22.6-58.6%), respectively. Non-relapse mortality (NRM) was 9.4 %. Conclusion: The results suggested that low dose ATG with low dose PTCy as GvHD prophylaxis in Haplo-PBSCT had promising activity.